Rheumatologists gathered from across the country last week to discuss the latest approaches in the treatment of rheumatoid arthritis (RA) and other inflammatory diseases at the American College of Rheumatology’s (ACR) 2018 State-of-the-Art (SOTA) Clinical Symposium held in Chicago, Illinois.
Rheumatologists gathered from across the country last week to discuss the latest approaches in the treatment of rheumatoid arthritis (RA) and other inflammatory diseases at the American College of Rheumatology’s (ACR) 2018 State-of-the-Art (SOTA) Clinical Symposium held in Chicago, Illinois.
Joan M. Bathon, MD, of the Columbia University Medical Center, provided an overview of different treatment strategies, a summary of currently approved agents and their comparative effectiveness, and some new agents being used in RA treatment.
Treatment Strategies
Bathon encouraged fellow rheumatologists to “treat early and treat hard.” She explained that initiating disease-modifying anti-rheumatic (DMARD) treatment within 6 weeks of diagnosis or recognition of symptoms maximizes damage prevention and minimizes disability. Early treatment combined with “treating hard,” or using the maximal efficacious dose tolerated by the patient, can lead to better outcomes.
In addition, Bathon noted that rapid escalation of a DMARD has also been shown to be more effective in treatment. For example, Bathon recommended escalating a dose of methotrexate to 20 mg per week by week 8 of treatment.
The third strategy Bathon discussed was to treat with a combination of DMARDs when appropriate, as combination therapy has been found to be consistently more effective than monotherapy. “It’s not 1 study that I can think of—there’s so many studies of treatment of RA now, but I don’t remember 1 that doesn’t show that combination therapy isn’t better than monotherapy,” said Bathon.
Comparison of Therapies
Bathon next discussed results from the BeSt study1, a randomized controlled trial that she explained was “one of the most important studies in the treatment of rheumatoid arthritis from a strategy perspective.” The study, which took place in the Netherlands, looked to evaluate outcomes from 4 different treatment strategies:
The goal of the study was to reach a disease activity score (measured in 44 joints) of less than 2.4. If this goal was not achieved by a particular treatment group in 3 months, the treatment was changed. The study found that, at 24 months, the groups were exactly identical in terms of disease activity score despite receiving different therapies. However, Bathon did note that remission was achieved more quickly if initial treatment began with combination therapy.
New Directions in Treatment
A new anti-IL6 monoclonal antibody, sarilumab, was found to be somewhat more efficacious than adalimumab for American College of Rheumatology (ACR) responses in a head-to-head clinical trial.
The safety profile of sarilumab was found to be similar to that of tocilizumab, with the most notable observed adverse event being neutropenia in about 35 patients (n = 582).
Additionally, Bathon presented on sirukumab, an anti-interleukin-6 monoclonal drug that was rejected by the FDA last August due to a higher number of deaths in the sirukumab group compared with placebo in a trial. The causes of these deaths were found to be cardiovascular events, infections, and malignancies.
Finally, Bathon closed with a few statements about biosimilars, explaining the FDA approval process and how they are developed. When asked if biosimilars will become first-line biologic therapies, Bathon said, “Possibly, for patients who are naïve to the bio-originator product in question.”
However, citing the NOR-SWITCH study,2 Bathon also stressed that there was no great toxicity or loss of efficacy found when switched from infliximab to CT-P13, an infliximab biosimilar, in the study.
References
1. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthrits Rheum. 2005;52(11):3381-3390. doi: 10.1002/art.21405.
2. Jorgensen K, Olsen I, Goll G, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomized, double blind, non-inferiority trial. Lancet. 2017;389(10086):2304-2316. doi: 10.1016/S0140-6736(17)30068-5.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
AAD Posters Examine Clinical Effects of Switching to Ustekinumab, Adalimumab Biosimilars
March 20th 2024Two posters presented at the American Academy of Dermatology (AAD) annual meeting examined the effects of switching from reference ustekinumab and adalimumab to biosimilar versions in patients with different types of psoriasis.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.